Under the direction of Rebecca Gruchalla, M.D., Ph.D., the Division of Allergy and Immunology in the Department of Internal Medicine (IM) and the Division of Pediatric Allergy and Immunology in the Department of Pediatrics work as one team. While administratively separate, the two Allergy and Immunology divisions function as one, blending teaching, clinical, and research.

Patient care and clinical activities are based at the Asthma, Allergy and Immunology, and Immunodeficiency Clinics at Children’s Health, Parkland Memorial Hospital and UT Southwestern, where division faculty provide comprehensive evaluation, diagnostic, and management services for children and adults, respectively, with allergy, asthma, and immunological disorders.

Faculty members participate in both clinical and basic science research efforts. As both a clinical and mechanistic site in the National Institutes of Health (NIH) Inner City Asthma Consortium (ICAC), the Division continues to expand research efforts in pediatric asthma. Moreover, Drs. Bird and Parrish perform important clinical research in food allergy and Dr. Khan in drug allergy and asthma. The Clinical Immunology Program is recognized as a Jeffrey Modell Foundation Diagnostic and Research Center.

The Division has one of only 78 ACGME-accredited programs for fellowship training in allergy and immunology. Division faculty also provide the major instruction to pediatric and internal medicine residents in the evaluation and management of children and adults with allergic diseases, asthma, and immunodeficiency diseases.

**Division Faculty**

Allergy and immunology spans both Pediatrics and Internal Medicine, with four pediatric-based and three internal medicine-based faculty members who are all certified by the American Board of Allergy and Immunology. All division faculty are clinically active and firmly committed to clinical teaching. Volunteer faculty members in private practice also participate in clinical and educational activities.
Rory Nicolaides, MD
Assistant Professor

B.S – Magna Cum Laude,
Bachelor of Science in Biology
University of North Florida, Jacksonville, FL, 2010

M.D.
University of Florida College of Medicine, Gainesville, FL 2015

Postdoctoral Training
Residency, Pediatrics
UT Southwestern Medical Center, 2015-2018

Fellowship, Pediatric Allergy & Immunology
UT Southwestern Medical Center, 2018-2020

Interests
Pediatric general allergy, food allergy, asthma, eczema, urticaria, drug allergy, and immunodeficiency

Honors / Awards

Best Doctors/Pediatric Specialists in Dallas, D Magazine
- Drew Bird
- Rebecca Gruchalla
- Christopher Parrish
- Christian Wysocki

Texas Super Doctors, Texas Monthly
- Drew Bird
- Rebecca Gruchalla
- David Khan
- Christopher Parrish (2020 Texas Rising Star)

Exceptional Women in Medicine, Castle Connolly Top Doctors
- Rebecca Gruchalla

Christopher Parrish
- American College of Allergy, Asthma and Immunology, Fellow

Invited Lectures
Rebecca Gruchalla
- American Academy of Allergy, Asthma and Immunology Annual Meeting, Philadelphia, PA March 2020
  - “The impact of environmental exposures on at-risk pediatric populations”
Drew Bird

- American Academy of Allergy, Asthma, and Immunology Annual Meeting, Philadelphia, PA, March 2020
  - “Managing Food Allergy from the Medical Perspective”
- American Academy of Allergy, Asthma, and Immunology Annual Meeting, Philadelphia, PA, March 2020
  - “Summary of the Updated Workgroup Report on Conducting Oral Food Challenges”
- Pediatric Academic Societies Meeting, Philadelphia, PA, May 2020
  - “Peanut Immunotherapy in 2020 – Are we ready?”
- Allergy, Asthma and Immunology Society of Georgia, Pine Mountain, GA, May 2020
  - “Updates in Food Allergy Treatment”

Jeffrey Chambliss

- Texas Health Presbyterian Hospital Internal Medicine Grand Rounds, Dallas, TX, February 2020
  - “Update in Asthma: Understanding Treatment Options”

Christopher Parrish

- Magellan Health Webcast, Virtual, February 2020
  - “Cracking Peanut Allergies”
- TexMed 2020, Allergy, Asthma, Immunology CME Program, Fort Worth, TX, May 2020
  - “Food Allergy: When IgE Tests are Negative”

Education and Training

The Division of Pediatric Allergy and Immunology is committed to providing quality medical education for medical students, residents, and fellows. It has an active fellowship program and also provides inpatient and outpatient opportunities for residents and medical students.

Fourth-Year Medical Students

Pediatric Allergy and Immunology offers a fourth-year clerkship for medical students. This course provides an in-depth exposure to pediatric allergy and immunology via:

- Clinical experience
- One-on-one discussions between student and faculty regarding pre-determined topics outside of the clinic
- Attending structured didactic sessions/conference
- Self-study through prepared curriculum material

Residents

The Pediatric Allergy and Immunology Division provides the major instruction to pediatric and internal medicine residents in the evaluation and management of children and adults with allergic diseases, asthma, and immunodeficiency diseases. It also provides didactic teaching for the residents on the basics of allergy and immunology and directs teaching for the residents in the regular departmental clinical conferences and as part of the inpatient consultation service.
An Allergy and Immunology elective is available for pediatric and internal medicine residents, and fourth-year medical students. The objectives of the elective are to:

- Develop a working differential diagnosis of allergies, asthma, and primary immunodeficiency disorders.
- Learn how to conduct a complete physical exam including the upper and lower airways.
- Examine and discuss patients from all major allergy and immunology categories: allergic rhinitis, asthma, urticaria, drug allergy, food allergy, and primary immunodeficiency.

Residents see outpatients in the clinics under the supervision of one of the members of the Division faculty. Relevant articles about specific allergic and immunologic disorders are provided to residents at the beginning of each rotation, and residents attend clinical conferences offering didactic teaching for fellows.

**Fellows**

Although recognized for its scientific achievements, the Division of Pediatric Allergy and Immunology is committed to excellence in clinical care and teaching. Toward this end, the Allergy and Immunology Training Program, directed by David Khan, M.D., has grown in both size and stature with four funded fellowship positions since it enrolled its first fellow in 1982.

**Balanced Clinical Experiences**

Successful training in Allergy and Immunology should consist of balanced exposure to training experiences involving adults and children, no matter what the training background or the long-term plans of any particular fellow in training. Drs. Rebecca Gruchalla, David Khan and Chris Wysocki oversee the adult teaching clinics at Parkland Memorial Hospital and the University West Campus, while Drs. Drew Bird, Chris Parrish, Jeffreyy Chambliss, Chris Wysocki, and Rory Nicolaides oversee the teaching clinics at Children’s Health™.

Further staffing of both adult and pediatric clinics is provided by our 15 volunteer clinical faculty. Approximately 40 percent of Allergy fellows have come from pediatric house staff programs, and approximately half of the outpatient clinics required of Allergy and Immunology fellows primarily involve children.

**Diversified Training Experiences**

The UT Southwestern program offers a diversity of clinical experiences in Allergy and Immunology. It has a strong primary immunodeficiency program and is one of the Diagnostic and Research Centers for the Jeffrey Modell Centers Network. In addition, a Food Allergy Center has been established for clinical and research purposes at Children’s Health™. The Food Allergy Center has been recognized as a FARE Clinical Network Center of Excellence since 2015 and was awarded the designation as a Discovery Center of Distinction in 2020.

The Adult Allergy Division operates the Parkland Asthma Clinic, which oversees the care of adult patients with moderate to severe asthma, and the Parkland Allergy Clinic and the clinics at the University’s West Campus are tertiary/quaternary referral centers for patients with chronic urticaria, drug allergies, hereditary angioedema, common variable immunodeficiency, mastocytosis, and anaphylaxis.

Fellows also have exposure to other common conditions including rhinitis, asthma, sinusitis, and atopic dermatitis in both the pediatric and adult clinics.
Research

All fellows are required to participate in at least one research project. Current and past projects have been extremely diverse – most are clinically oriented and some are basic science-oriented – a reflection of the differing interests of the past and current fellows. Because training positions are fully funded by Parkland Memorial Hospital and Children’s Medical Center, and not by federal training grants, fellows are encouraged to consider research opportunities in a diversity of fields.

Fellows are encouraged to present the results of their research studies at national meetings. The majority of fellows are able to publish at least one manuscript based on their fellowship training. Fellows in training are encouraged to travel to one national meeting during each of the two training years and are provided financial support for this purpose.

Success of Training Program Graduates

Within the past 16 years, 100 percent of the graduates of UT Southwestern’s Allergy and Immunology training program have passed the American Board of Allergy and Immunology certifying examination. Most graduates are currently in private or group practice settings; however, a few have become full-time medical school faculty members. More than half of our clinical faculty are prior graduates of the Allergy and Immunology training program.

Research Activities

Since 1994, Dr. Gruchalla has had sustained NIH funding for research in inner-city pediatric asthma. In 1996, she became a member of the Inner-City Asthma Multicenter Study group (Dallas-site PI), which became an NIH-sponsored contract (Inner City Asthma Consortium – ICAC) in 2002. The initial contract was a six-year contract for $55.8 million, and its purpose was to investigate the mechanisms of asthma in inner-city children, as well as to develop novel treatments for this disease. The contract has been renewed for the third time and now extends through 2021.

UT Southwestern Medical Center is once again a participating site, along with Boston University, Children’s Memorial Hospital in Chicago, Cincinnati’s Children’s in Cincinnati, Children’s National Medical Center in Washington, D.C., Henry Ford Health System in Detroit, National Jewish Health in Denver, Johns Hopkins University in Baltimore, Columbia University in New York, St. Louis Children’s Hospital in St. Louis, and the University of California, San Francisco.

UT Southwestern continues to be one of the top recruiting sites for ICAC.

In addition to the asthma clinical studies that have been, and that are being done, as a part of ICAC, basic mechanistic studies are being conducted as well.

Drs. Rebecca Gruchalla and Michelle Gill, Professor of Pediatrics, Immunology and Internal Medicine, are involved in research that suggests allergic reactions to cockroaches, pet dander, dust mites, and mold may prevent people with allergic asthma from generating appropriate immune responses to respiratory challenges like the flu virus.

Dr. David Khan is conducting various research projects in adults focused on drug allergies, refractory chronic urticaria, mood disorders and asthma, and rush immunotherapy.

Dr. Bird continues conducting active research into interventional therapeutics for treatment of life-threatening food allergies. In 2019, Dr. Bird was invited to participate in the NIH/NIAID-funded Consortium for Food Allergy Research. In 2020 Drs. Bird and Parrish were awarded the FARE Clinical Network Discovery Center of Designation grant, providing $50,000 per year through 2025.
Dr. Wysocki collaborates with Dr. Nicolai Van Oers in the basic Immunology department on projects related to novel gene discovery in primary immunologic disorders, and on various aspects of DiGeorge/22q11.2 deletion syndrome. In collaboration with Dr. Victor Aquino from the Stem Cell Transplant team, the program is involved in clinical research through the Primary Immunodeficiency Treatment Consortium (PIDTC).

**Clinical Activities**

Faculty cover an active consult service at Children’s Health, Parkland Memorial Hospital, and UT Southwestern University Hospitals, as well as outpatient clinic services in Asthma, Allergy, and Immunology at Children’s and the University’s West Campus.

**Clinical Immunology Program**

The Clinical Immunology Program was awarded recognition by the Jeffrey Modell Foundation as a Diagnostic and Research Center primary immunodeficiency diseases. Directed by Dr. Christian Wysocki and with the new addition of Dr. Rory Nicolaides, the Clinical Immunology Program serves a large geographical referral area encompassing North Texas, eastern New Mexico, Oklahoma, western Louisiana, and southern Arkansas. This comprehensive program provides both diagnostic and state-of-the-art treatment opportunities for patients with primary immunodeficiency diseases. The clinical program also partners with members of the basic Immunology department at UT Southwestern in research and educational efforts.

Furthermore, Dr. Wysocki staffs adult Immunodeficiency clinics at UT Southwestern and Parkland Hospital. This allows state of the art treatment of adult patients with immunodeficiency disorders, and importantly, allows effective transitioning of adolescent and young adult patients from the pediatric immunodeficiency clinics, to the adult clinics, while maintaining continuity of care.

**Food Allergy Center**

Under the direction of Dr. Drew Bird, Dedman Family Scholar in Clinical Care, the Food Allergy Center treats a broad range of allergic diseases in both inpatient and outpatient settings and will be conducting research that is instrumental in developing treatments and therapies. This Center opened in 2010 and is the only academic-affiliated pediatric food allergy center in North Texas. Since 2015 the Food Allergy Center has been recognized as a FARE Clinical Network Center of Excellence and in 2020 received designation as a Clinical Network Discovery Center of Distinction.

The Food Allergy Center is also home to the Dallas Eosinophilic Esophagitis Program (DEEP) at Children’s Health. Dr. Christopher Parrish is Co-Director of this multidisciplinary program, which utilizes a team approach to the management of eosinophilic esophagitis involving a pediatric allergist, pediatric gastroenterologists, a dietitian and a child psychologist with expertise in feeding problems.

**Asthma and Allergy Clinic**

In addition to other allergic diseases, Drs. Jeffrey Chambliss and Rory Nicolaides evaluate and care for children with persistent allergic asthma along with a volunteer faculty member, Dr. William Neaville. The targeted therapies for these patients may include biologic therapies and/or allergy shots offered through the immunotherapy clinic. The immunotherapy clinic also treats patients with allergic rhinitis and utilizes biologic therapy in the care of patients with chronic urticaria.
**Patient Visits**
Allergy and Immunology Patient Visits By Type Per Location By Year.

<table>
<thead>
<tr>
<th>Location</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dallas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food allergy new patient visits</td>
<td>956</td>
<td>912</td>
<td>740</td>
<td>667</td>
</tr>
<tr>
<td>Food allergy follow up visits</td>
<td>719</td>
<td>752</td>
<td>819</td>
<td>901</td>
</tr>
<tr>
<td>Food allergy challenge visits</td>
<td>524</td>
<td>429</td>
<td>652</td>
<td>463</td>
</tr>
<tr>
<td>Allergy new patient visits</td>
<td>677</td>
<td>777</td>
<td>1294</td>
<td>794</td>
</tr>
<tr>
<td>Allergy follow up visits</td>
<td>724</td>
<td>830</td>
<td>1079</td>
<td>1049</td>
</tr>
<tr>
<td>Immunology new patient visits</td>
<td>339</td>
<td>251</td>
<td>242</td>
<td>277</td>
</tr>
<tr>
<td>Immunology follow up visits</td>
<td>495</td>
<td>468</td>
<td>465</td>
<td>485</td>
</tr>
<tr>
<td>Total Dallas Visits</td>
<td>4,434</td>
<td>4,419</td>
<td>5,291</td>
<td>4,636</td>
</tr>
<tr>
<td>Legacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food allergy new patient visits</td>
<td>423</td>
<td>632</td>
<td>654</td>
<td>504</td>
</tr>
<tr>
<td>Food allergy follow up visits</td>
<td>241</td>
<td>275</td>
<td>397</td>
<td>512</td>
</tr>
<tr>
<td>Food allergy challenge visits</td>
<td>25</td>
<td>9</td>
<td>13</td>
<td>10</td>
</tr>
<tr>
<td>Total Legacy Visits</td>
<td>689</td>
<td>916</td>
<td>1,064</td>
<td>1,026</td>
</tr>
<tr>
<td>THD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food allergy new patient visits</td>
<td></td>
<td></td>
<td>112</td>
<td>127</td>
</tr>
<tr>
<td>Food allergy follow up visits</td>
<td></td>
<td></td>
<td>109</td>
<td>133</td>
</tr>
<tr>
<td>Total THD Visits</td>
<td></td>
<td></td>
<td>221</td>
<td>260</td>
</tr>
</tbody>
</table>

Total All Locations

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total New, follow up, and challenge visits</td>
<td>5,123</td>
<td>5,556</td>
<td>6,615</td>
<td>5,901</td>
</tr>
</tbody>
</table>

**Current Grant Support**

**Drew Bird**

**Grantor:** Aimmune Therapeutics  
**Title of Project:** Peanut Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)  
**Role:** Site Principal Investigator  
**Dates:** 04/2016 – 04/2021

**Grantor:** Aimmune Therapeutics  
**Title of Project:** Real-world AR101 market supporting experience study in peanut-allergic children ages 4 to 17 (RAMSES)  
**Role:** Site Principal Investigator  
**Dates:** 03/2016 – 6/2020

**Grantor:** Astellas Pharma  
**Title of Project:** A Phase 1, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut after Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3)  
**Role:** Site Principal Investigator  
**Dates:** 05/2019 – 10/2022
Grantor: DBV Technologies  
**Title of Project:** A Double-Blind, Placebo-Controlled Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgE-Mediated Cow’s Milk Allergy in Children (MILES study)  
**Role:** Site Principal Investigator  
**Dates:** 07/2015 – 06/2020

Grantor: DBV Technologies  
**Title of Project:** A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut allergic young children 1 to 3 years of age  
**Role:** Site Sub-Investigator  
**Dates:** 02/2019 – 01/2024

Grantor: DBV Technologies  
**Title of Project:** Long-term Assessment of Safety and Therapeutic Benefit of Viaskin Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-Month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by an Open Label Active Treatment (REALISE Study)  
**Role:** Site Principle Investigator  
**Dates:** 12/2016 – 12/2020

Grantor: DBV Technologies  
**Title of Project:** Open-label Follow-up Study of the PEPITES Study to Evaluate the long-term efficacy and safety of Viaskin Peanut (PEOPLE Study)  
**Role:** Site Principal Investigator  
**Dates:** 04/2017 – 03/2020

Grantor: Food Allergy Research and Education  
**Title of Project:** Peanut Sublingual Immunotherapy Induction of Clinical Tolerance in Newly Diagnosed Peanut Allergic 12 to 48 month-old Children  
**Role:** Site Principal Investigator  
**Dates:** 05/2014 – 12/2020

Grantor: Food Allergy Research and Education  
**Title of Project:** Clinical Network Discovery Center of Distinction  
**Role:** Site Principal Investigator and Program Director  
**Dates:** 06/2020-06/2025

Grantor: NIH-NIAID and Genentech  
**Title of Project:** Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)  
**Role:** Site Principal Investigator  
**Dates:** 03/2019 – 02/2024

Grantor: NIH-NIAID and Johns Hopkins  
**Title of Project:** New Horizons in the Prevention and Treatment of Food Allergy  
**Role:** Principal Investigator  
**Dates:** 03/2019 –02/2024

Grantor: Miller Family Foundation  
**Title of Project:** Intestinal microbiome and immune profiling in infants with food protein-induced enterocolitis syndrome (FPIES)  
**Role:** Principal Investigator  
**Dates:** 2019- 2025
Grantor: Regeneron Pharmaceuticals, Inc.
Title of Project: A Phase 3, Randomized, 3 Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (R668-EE-1774)
Role: Site Sub-Investigator
Dates: 07/2019 – 12/2040

Grantor: Thrasher Foundation
Title of Project: Mendelian Causes of Allergic Sensitization
Role: Co-Investigator
Dates: 8/2019 -2023

Jeffrey Chambliss

Grantor: University of Wisconsin / NIAID
Title of Project: Inner City Asthma Consortium
Role: Co-Investigator
Dates: 2019 – 2021

Rebecca Gruchalla

Grantor: University of Wisconsin / NIAID
Title of Project: Inner City Asthma Consortium
Role: Principal Investigator
Dates: 2014 – 2021

Christopher Parrish

Grantor: Aimmune Therapeutics
Title of Project: Peanut Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Role: Site Sub-Investigator
Dates: 04/2016 – 04/2021

Grantor: Aimmune Therapeutics
Title of Project: Real-world AR101 market supporting experience study in peanut-allergic children ages 4 to 17 (RAMSES)
Role: Site Sub-Investigator
Dates: 03/2016 – 06/2020

Grantor: Astellas Pharma
Title of Project: A Phase 1, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut after Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3)
Role: Site Sub-Investigator
Dates: 05/2019 – 10/2022

Grantor: DBV Technologies
Title of Project: A Double-Blind, Placebo-Controlled Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgE-Mediated Cow’s Milk Allergy in Children (MILES study)
Role: Site Sub-Investigator
Dates: 07/2015 – 06/2020
Grantor: DBV Technologies
**Title of Project:** A Double-Blind, Placebo-Controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-Allergic Young Children 1-3 Years of Age (Epitope)
**Role:** Principal Investigator
**Dates:** 02/2019 – 02/2024

Grantor: DBV Technologies
**Title of Project:** Long-term Assessment of Safety and Therapeutic Benefit of Viaskin Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-Month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by an Open Label Active Treatment (REALISE Study)
**Role:** Site Sub-Investigator
**Dates:** 12/2016 – 12/2020

Grantor: DBV Technologies
**Title of Project:** Open-label Follow-up Study of the PEPITES Study to Evaluate the long-term efficacy and safety of Viaskin Peanut (PEOPLE Study)
**Role:** Site Sub-Investigator
**Dates:** 04/2017 – 03/2020

Grantor: Regeneron Pharmaceuticals, Inc.
**Title of Project:** A Phase 3, Randomized, 3 Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (R668-EE-1774)
**Role:** Principal Investigator
**Dates:** 07/2019 – 12/2040

Grantor: Food Allergy Research and Education
**Title of Project:** Peanut Sublingual Immunotherapy Induction of Clinical Tolerance in Newly Diagnosed Peanut Allergic 12 to 48 month-old Children
**Role:** Site Sub-Investigator
**Dates:** 05/2014 – 12/2020

Grantor: NIH-NIAID and Genentech
**Title of Project:** Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUTMATCH)
**Role:** Site Sub-Investigator
**Dates:** 03/2019 – 02/2024

David Khan

Grantor: NHLBI-National Heart, Lung and Blood Institute
**Title of Project:** Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators
**Role:** Principal Investigator
**Dates:** 09/2015 – 06/2020

Grantor: NHLBI-National Heart, Lung and Blood Institute
**Title of Project:** The Dallas Asthma Brain and Cognition Study
**Role:** Principal Investigator
**Dates:** 07/2018 – 05/2022

Grantor: NATIONAL INSTITUTE OF HEALTH
**Title of Project:** Penicillin Allergy: Prediction, Outcomes, and Phenotypes
**Role:** Principal Investigator
**Dates:** 07/2020 – 06/2025  
**Grantor:** NATIONAL INSTITUTE OF HEALTH  
**Title of Project:** Determining the Accuracy of Cephalosporin Allergy Testing  
**Role:** Principal Investigator  
**Dates:** 06/2019 – 05/2021

**Christian Wysocki**

**Grantor:** Jeffrey Modell Foundation  
**Title of Project:** Primary Immune Deficiency Diagnostic and Research Center  
**Title:** Director  
**Dates:** 09/2020 – 09/2021

**Journal Publications**


Book Chapters